John A. Thompson, MD
Department of Medicine
Division of Oncology
Seattle Cancer Care Alliance
825 Eastlake Ave E, CE2-128
Seattle, WA 98109-1023
Specialty / Expertise
Melanoma and Renal Cancer
- Director, Phase 1 Clinical Trials Program, UW/FHCRC
- Activated lymphocytes and cytokines
Current Research Projects
A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly with Sorafenib (Nexavar) in Subjects with Metastatic Renal Cell Carcinoma.
Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin) + Temsirolimus (Torisel) vs. Bevacizumab (Avastin) + Interferon-Alfa (Roferon) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma.
A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for first-line treatment of patients with metastatic clear cell carcinoma of the kidney.
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma.
Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and /or Metastatic Renal Cell Carcinoma.
An open-label, dose escalation, Phase I study of MLN9708, a second generation proteasome inhibitor, in adult patients with advanced non-hematologic malignancies.
A Phase I, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-75 in patients with relapsed or refractory CD70-positive non-Hodgkin Lymphoma or renal cell carcinoma.
A multi-center, open-label, dose-escalation study to assess the pharmacokinetics of intravenous ASA404 in adult advanced cancer patients with impaired renal function and with normal renal function.
A Phase II Study to Evaluate the Relationship between IMC-1121B Therapy and Corrected QT (QTc) Interval Changes in Patients with Advanced Cancer
A Phase Ib/II Study of ALT-801 with Cisplatin in Patient with Metastatic Melanoma.
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects with Advanced Renal Cell Carcinoma
A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Subjects with Pancreatic Adenocarcinoma
A Phase 1b Study of LY573636-sodium in Combination with Sunitinib Malate (Sutent) in Patients with Metastatic Renal Cell Cancer
Dr. Thompson received his MD from University of Alabama, Birmingham, AL. He completed his Internal Medicine Residency at the University of Washington, Seattle, WA. He was a Post-Doctoral Fellow in Oncology at the University of Washington, Seattle, WA.
Thompson, J.A., Lee, D.J., Cox, W.W., Lindgren, C.G., Collins, C., Neraas, K.A., Dennin, R.A., and Fefer, A.: Recombinant interleukin-2: Toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res. 47:4202-4207, 1987.
Thompson, J.A., Lee, D.J., Lindgren, C.G., Benz, L.A., Collins, C., Levitt, D.J., and Fefer, A.: Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J. Clin. Oncol. 6:669-678, 1988.
Thompson, J.A., Lee, D.J., Lindgren, C.G., Benz, L.A., Collins, C., Shuman, W.P., Levitt, D.J., and Fefer, A.: Influence of schedule of interleukin-2 administration on therapy with interleukin-2 and lymphokine-activated killer cells. Cancer Research 49:235-240, 1989.
Thompson, J.A., Shulman, K.L., Benyunes, M.C., Collins, C., Lange, P.H., Bush, W.H., Lindgren, C.L., Benz, L.A., & Fefer, A.: Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 10:960-968, 1992.
Thompson, J.A., Bianco, J.A., Benyunes, M.C., Neubauer, M., Slattery, J.T., and Fefer, A.: Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res. 54:3436-41, 1994.
Figlin, R.A., Thompson, J.A., Bukowski, R.M., Vogelzang, N.J., Novick, A.C., Lange, P., Steinberg, G., and Belldegrun, A.S. Multicenter, randomized, phase II/III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma, J. Clin. Oncol., 17:2521-2529, 1999.
Thompson, J.A., Gilliland, D.G., Prchal, J.T., Bennett, J.M., Larholt, K., Nelson, R.A., Rose, E.H., Dugan, M.H., and the GM/EPO MDS Study Group. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175-1179, 2000.
Yee, C., Thompson, J.A., Byrd, D., Riddell, S.R., Roche, P., Cellis, E., and Greenberg, P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci USA 99(25):16168-73, 2002.
Thompson, J.A., Figlin, R.A., Sifri-Steele, C., Berenson, R.J., and Frohlich, M.W. A Phase I trial of CD3/CD28 activated T cells (Xcellerated T cellsTM) and IL-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 9:3562-3560, 2003
Mitchell, M.S., Abrams, J., Thompson, J.A., et al Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 25:2078-2085, 2007
Thompson, J.A., Curti, B.D., Redman, B.G., Bhatia, S., Weber, J.S., Agarwala, S.S., Sievers, E.L., Hughes, S.D. DeVries, T.A., and Hausman, D.F. Phase 1 study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol, 26:2034-2039, 2008.
Thompson, J.A., Fisher, R.I., LeBlanc, M., Forman, S.J., Press, O.W., Unger, J.M., Nademanee, A.P., Stiff, P.J., Petersdorf, S.H., Fefer, A. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem cell transplantation followed by randomization to therapy with Interleukin-2 versus observation for patients with non-Hodgkin’s lymphoma: Results of a Phase III randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 111:4048-4054, 2008.
Hunder, N., Wallen, H., Cao, J., Hendricks, D., Reilly, J.Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J.A., and Yee, C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703, 2008.
Thompson, J. A., Kuzel, T., Drucker, B. J., Urba, W.J., and Bukowski, R.M., Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter Phase I/II study. Clinical Genitourinary Cancer, 7 (3): E58-E65, 2009.
Weber, J., Thompson, J.A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., Siegel, J., O’Day, S.J. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Can Research 15(17):5591-5598, 2009.
Last updated: May 2011